Uptake / Timing ~ Risk-Reducing Mastectomy
~ Genetics of Breast & Ovarian Cancer

List was last updated on Nov 19, 2019 @ 8:30 pm.


    • Prophylactic nipple-sparing mastectomy in young previvors: Examining decision-making, reconstructive outcomes, and patient satisfaction in BRCA+ patients under 30.
    • Salibian AA, Bekisz JM, Frey JD, Miller B, Choi M, Karp NS.
    • Breast J. 2019 Nov 17. doi: 10.1111/tbj.13692. [Epub ahead of print]
    • Impact of Genetic Testing on Risk-Management Behavior of Black Breast Cancer Survivors: A Longitudinal, Observational Study.
    • Conley CC, Kasting ML, Augusto BM, Garcia JD, Cragun D, Gonzalez BD, Kim J, Ashing KT, Knott CL, Hughes-Halbert C, Pal T, Vadaparampil ST.
    • Ann Surg Oncol. 2019 Nov 1. doi: 10.1245/s10434-019-07982-9. [Epub ahead of print]
    • Hereditary breast cancer: screening and risk reducing surgery.
    • Renzulli M, Zanotti S, Clemente A, Mineo G, Tovoli F, Reginelli A, Barile A, Cappabianca S, Taffurelli M, Golfieri R.
    • Gland Surg. 2019 Sep;8(Suppl 3):S142-S149. doi: 10.21037/gs.2019.04.04.
    • Breast reconstruction after risk-reducing mastectomy in BRCA mutation carriers.
    • Nagura N, Hayashi N, Takei J, Yoshida A, Ochi T, Iwahira Y, Yamauchi H.
    • Breast Cancer. 2019 Jul 10. doi: 10.1007/s12282-019-00995-y. [Epub ahead of print]
    • Risk-reducing surgery in BRCA1/BRCA2 mutation carriers: are there factors associated with the choice?
    • Manoukian S, Alfieri S, Bianchi E, Peissel B, Azzollini J, Borreani C.
    • Psychooncology. 2019 Jul 1. doi: 10.1002/pon.5166. [Epub ahead of print]
    • Clinical characteristics and outcomes in elderly women with BRCA1 and BRCA2 mutations.
    • Salyer C, Kobelka C, Barrie A, Weintraub MR, Powell CB.
    • Gynecol Oncol. 2019 May 31. pii: S0090-8258(19)31261-2. doi: 10.1016/j.ygyno.2019.05.017. [Epub ahead of print]
    • International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation.
    • Metcalfe K, Eisen A, Senter L, Armel S, Bordeleau L, Meschino WS, Pal T, Lynch HT, Tung NM, Kwong A, Ainsworth P, Karlan B, Moller P, Eng C, Weitzel JN, Sun P, Lubinski J, Narod SA; Hereditary Breast Cancer Clinical Study Group.
    • Br J Cancer. 2019 Apr 11. doi: 10.1038/s41416-019-0446-1. [Epub ahead of print]

    Editorial:

    Cancer screening and prevention in BRCA mutation carriers: a missed opportunity?

    • Evolving indications and long-term oncological outcomes of risk-reducing bilateral nipple-sparing mastectomy.
    • Grobmyer SR, Pederson HJ, Valente SA, Al-Hilli Z, Radford D, Djohan R, Yetman R, Eng C, Crowe JP.
    • BJS Open. 2018 Nov 26;3(2):169-173. doi: 10.1002/bjs5.50117. eCollection 2019 Apr.
    • A clinically structured and partnered approach to genetic testing in Trinidadian women with breast cancer and their families.
    • Donenberg T, George S, Ali J, Bravo G, Hernandez K, Sookar N, Ashing KT, Narod SA, Akbari MR, Hurley J.
    • Breast Cancer Res Treat. 2019 Apr;174(2):469-477. doi: 10.1007/s10549-018-5045-y. Epub 2018 Dec 4.
    • Current knowledge of risk reducing mastectomy: Indications, techniques, results, benefits, harms.
    • Baildam AD.
    • Breast. 2019 Mar 29;46:48-51. doi: 10.1016/j.breast.2019.03.011. [Epub ahead of print]
    • Review
    • Trends in use of bilateral prophylactic mastectomy vs high-risk surveillance in unaffected carriers of inherited breast cancer syndromes in the Inherited Cancer Registry (ICARE).
    • Henry DA, Lee MC, Almanza D, Ahmed KA, Sun W, Boulware DC, Laronga C.
    • Breast Cancer Res Treat. 2019 Feb;174(1):39-45. doi: 10.1007/s10549-018-5057-7. Epub 2018 Nov 24.
    • Selected medical interventions in women with a deleterious BRCA mutation: a population-based study in British Columbia.
    • Hanley GE, McAlpine JN, Cheifetz R, Schrader KA, McCullum M, Huntsman D.
    • Curr Oncol. 2019 Feb;26(1):e17-e23. doi: 10.3747/co.26.4068. Epub 2019 Feb 1.
    • Prophylactic Versus Therapeutic Mastectomy: A Contemporary Analysis of the ACS-NSQIP Database.
    • Hendrix RJ, Lee C, Friedrich AK, Rouanet E, Larkin AC, LaFemina J.
    • Clin Breast Cancer. 2019 Jan 31. pii: S1526-8209(19)30050-3. doi: 10.1016/j.clbc.2019.01.008. [Epub ahead of print]
    • High patient satisfaction with a simplified BRCA1/2 testing procedure: long-term results of a prospective study.
    • Nilsson MP, Nilsson ED, Borg Å, Brandberg Y, Silfverberg B, Loman N.
    • Breast Cancer Res Treat. 2019 Jan;173(2):313-318. doi: 10.1007/s10549-018-5000-y. Epub 2018 Oct 11.
    • Cancer Risk Estimates for Study of Multiple-Gene Testing After Diagnosis of Breast Cancer.
    • Narod SA.
    • JAMA Oncol. 2018 Dec 1;4(12):1787-1788. doi: 10.1001/jamaoncol.2018.4931.
    • Letter, Comment

    Original Research:

    Uptake, Results, and Outcomes of Germline Multiple-Gene Sequencing After Diagnosis of Breast Cancer.

    Letter, reply:

    Cancer Risk Estimates for Study of Multiple-Gene Testing After Diagnosis of Breast Cancer—Reply

    • Real-world health services utilisation and outcomes after BRCA1 and BRCA2 testing in Ontario, Canada: the What Comes Next Cohort Study protocol.
    • Dossa F, Cusimano MC, Sutradhar R, Metcalfe K, Little T, Lerner-Ellis J, Eisen A, Meschino WS, Baxter NN.
    • BMJ Open. 2018 Sep 4;8(9):e025317. doi: 10.1136/bmjopen-2018-025317.
    • Risk-reducing mastectomy rates in the US: a closer examination of the Angelina Jolie effect.
    • Liede A, Cai M, Crouter TF, Niepel D, Callaghan F, Evans DG.
    • Breast Cancer Res Treat. 2018 Sep;171(2):435-442. doi: 10.1007/s10549-018-4824-9. Epub 2018 May 28.
    • Surgery for BRCA, TP53 and PALB2: a literature review.
    • Song CV, Teo SH, Taib NA, Yip CH.
    • Ecancermedicalscience. 2018 Aug 29;12:863. doi: 10.3332/ecancer.2018.863. eCollection 2018.
    • Uptake, Results, and Outcomes of Germline Multiple-Gene Sequencing After Diagnosis of Breast Cancer.
    • Kurian AW, Ward KC, Hamilton AS, Deapen DM, Abrahamse P, Bondarenko I, Li Y, Hawley ST, Morrow M, Jagsi R, Katz SJ.
    • JAMA Oncol. 2018 Aug 1;4(8):1066-1072. doi: 10.1001/jamaoncol.2018.0644.

    Press: Multigene Sequencing Rapidly Replacing BRCA Tests. (Medscape Oncology)

    Letter, Comment:

    Cancer Risk Estimates for Study of Multiple-Gene Testing After Diagnosis of Breast Cancer.

    Letter, Reply:

    Cancer Risk Estimates for Study of Multiple-Gene Testing After Diagnosis of Breast Cancer-Reply.

    • Uptake of risk-reducing surgery in BRCA gene carriers in Wales, UK.
    • Long J, Evans TG, Bailey D, Lewis MH, Gower-Thomas K, Murray A.
    • Breast J. 2018 Jul;24(4):580-585. doi: 10.1111/tbj.12978. Epub 2017 Dec 29.
    • Cancer risk management in Tasmanian women with BRCA1 and BRCA2 mutations.
    • Kearton S, Wills K, Bunting M, Blomfield P, James PA, Burke J.
    • Fam Cancer. 2018 Jul;17(3):333-344. doi: 10.1007/s10689-017-0047-1.
    • Immediate Breast Reconstruction: Comparative Outcome Study of One-Stage Direct-to-Implant and Two-Stage/Tissue Expander Techniques.
    • Meshulam-Derazon S, Shay T, Lewis S, Adler N.
    • Isr Med Assoc J. 2018 Jun;20(6):340-344.
    • Juliet's story: No reconstruction is a post-mastectomy option.
    • [No author given]
    • FORCE. XRAYS. 2018 May 24.

    Blog post: I felt empowered by choosing not to have a reconstruction. (Breast Cancer Care)

    • Risk management decisions in women with BRCA1 and BRCA2 mutations.
    • Morgan R, Brown A, Hamman KJ, Sampson J, Naik A, Massimino K.
    • Am J Surg. 2018 May;215(5):899-903. doi: 10.1016/j.amjsurg.2018.02.010. Epub 2018 Feb 13.
    • Genetic and clinical characteristics in Japanese hereditary breast and ovarian cancer: first report after establishment of HBOC registration system in Japan.
    • Arai M, Yokoyama S, Watanabe C, Yoshida R, Kita M, Okawa M, Sakurai A, Sekine M, Yotsumoto J, Nomura H, Akama Y, Inuzuka M, Nomizu T, Enomoto T, Nakamura S.
    • J Hum Genet. 2018 Apr;63(4):447-457. doi: 10.1038/s10038-017-0355-1. Epub 2017 Nov 8.
    • Short report: Follow-up of Bahamian women with a BRCA1 or BRCA2 mutation.
    • Narod SA, Butler R, Bobrowski D, Akbari MR, Curling D, Lunn J, Ho C, Panahi S, Llacuachaqui M, Donenberg T, Hurley J.
    • Mol Genet Genomic Med. 2018 Mar;6(2):301-304. doi: 10.1002/mgg3.363. Epub 2017 Dec 20.
    • The Use of Sentinel Lymph Node Biopsy in BRCA1/2 Mutation Carriers Undergoing Prophylactic Mastectomy: A Retrospective Consecutive Case-Series Study.
    • Câmara S, Pereira D, André S, Mira B, Vaz F, Oom R, Marques JC, Leal de Faria J, Rodrigues Dos Santos C.
    • Int J Breast Cancer. 2018 Jan 1;2018:1426369. doi: 10.1155/2018/1426369. eCollection 2018.
    • Differences Among a Modern Cohort of BRCA Mutation Carriers Choosing Bilateral Prophylactic Mastectomies Compared to Breast Surveillance.
    • Gilbert E, Zabor EC, Stempel M, Mangino D, Heerdt A, Pilewskie M.
    • Ann Surg Oncol. 2017 Oct;24(10):3048-3054. doi: 10.1245/s10434-017-5976-2. Epub 2017 Aug 1.
    • Clinical Decision-Making in Patients with Variant of Uncertain Significance in BRCA1 or BRCA2 Genes.
    • Welsh JL, Hoskin TL, Day CN, Thomas AS, Cogswell JA, Couch FJ, Boughey JC.
    • Ann Surg Oncol. 2017 Oct;24(10):3067-3072. doi: 10.1245/s10434-017-5959-3. Epub 2017 Aug 1.
    • BRCA Genetic Testing and Receipt of Preventive Interventions Among Women Aged 18-64 Years with Employer-Sponsored Health Insurance in Nonmetropolitan and Metropolitan Areas - United States, 2009-2014.
    • Kolor K, Chen Z, Grosse SD, Rodriguez JL, Green RF, Dotson WD, Bowen MS, Lynch JA, Khoury MJ.
    • MMWR Surveill Summ. 2017 Sep 8;66(15):1-11. doi: 10.15585/mmwr.ss6615a1.
    • Do All BRCA 1 and 2 Carriers with a Known and Unknown Breast Cancer Choose Bilateral Mastectomies?
    • Gaffley M, Villa A, Vu T, Steelman S, Howard-McNatt M.
    • Am Surg. 2018 Sep 1;84(9):1544-1545.
    • Quality of Patient Decisions About Breast Reconstruction After Mastectomy.
    • Lee CN, Deal AM, Huh R, Ubel PA, Liu YJ, Blizard L, Hunt C, Pignone MP.
    • JAMA Surg. 2017 Aug 1;152(8):741-748. doi: 10.1001/jamasurg.2017.0977.
    • Women at familial risk of breast cancer electing for prophylactic mastectomy: frequencies, procedures, and decision-making characteristics.
    • Schott S, Vetter L, Keller M, Bruckner T, Golatta M, Eismann S, Dikow N, Evers C, Sohn C, Heil J.
    • Arch Gynecol Obstet. 2017 Jun;295(6):1451-1458. doi: 10.1007/s00404-017-4376-y. Epub 2017 Apr 24.
    • Influence of the Angelina Jolie Announcement and Insurance Reimbursement on Practice Patterns for Hereditary Breast Cancer.
    • Lee J, Kim S, Kang E, Park S, Kim Z, Lee MH; Korean Breast Cancer Society.
    • J Breast Cancer. 2017 Jun;20(2):203-207. doi: 10.4048/jbc.2017.20.2.203. Epub 2017 Jun 26.
    • Innovative practice model to optimize resource utilization and improve access to care for high-risk and BRCA+ patients.
    • Head L, Nessim C, Usher Boyd K.
    • Can J Surg. 2017 Feb;60(1):37-44.
    • Outcomes of Concurrent Breast and Gynecologic Risk Reduction Surgery.
    • Ma IT, Gray RJ, Wasif N, Butler KA, Cornella JL, Magrina JF, Magtibay PM, Casey WJ, Mahabir R, Rebecca AM, Hunt KS, Pockaj BA.
    • Ann Surg Oncol. 2017 Jan;24(1):77-83. doi: 10.1245/s10434-016-5479-6. Epub 2016 Aug 31.
    • Do celebrity endorsements matter? Observational study of BRCA gene testing and mastectomy rates after Angelina Jolie's New York Times editorial.
    • Desai S, Jena AB.
    • BMJ. 2016 Dec 14;355:i6357. doi: 10.1136/bmj.i6357.

    Research News:

    Angelina Jolie's mastectomy triggered sharp rise in gene testing.

    Research News: Angelina Jolie spoke out on BRCA testing: Did genetic testing increase? (FORCE)

    Blog post: "Angelina Jolie Effect”: What Should I Know About Hereditary Cancer and Testing? (NSGC Blog)

    Research News: Were women foolish to follow Angelina Jolie into BRCA cancer gene testing? (STAT)

    Research News: Jolie Effect: BRCA Tests Up but No Change in Mastectomy. (Medscape)

    • Risk-reducing mastectomy.
    • Chiesa F, Sacchini V.
    • Minerva Ginecol. 2016 Oct;68(5):544-7. Epub 2016 Jan 19.
    • Review
    • Has the Angelina Jolie effect led to an increase in risk reducing mastectomy and breast reconstruction in Wales: A retrospective, single centre cohort study.
    • Malcolm CM, Javed MU, Nguyen D.
    • J Plast Reconstr Aesthet Surg. 2016 Feb;69(2):288-9. doi: 10.1016/j.bjps.2015.10.018. Epub 2015 Oct 26.
    • Letter
    • Surgical Decision Making in the BRCA-Positive Population: Institutional Experience and Comparison with Recent Literature.
    • Flippo-Morton T, Walsh K, Chambers K, Amacker-North L, White B, Sarantou T, Boselli DM, White RL Jr.
    • Breast J. 2016 Jan-Feb;22(1):35-44. doi: 10.1111/tbj.12521. Epub 2015 Dec 23.
    • Legislation regulating availability of breast cancer treatment with particular focus on prophylactic mastectomy.
    • Rolska P, Łapa J.
    • Folia Med Cracov. 2016;56(2):73-94.
    • Longer term effects of the Angelina Jolie effect: increased risk-reducing mastectomy rates in BRCA carriers and other high-risk women.
    • Evans DG, Wisely J, Clancy T, Lalloo F, Wilson M, Johnson R, Duncan J, Barr L, Gandhi A, Howell A.
    • Breast Cancer Res. 2015 Nov 25;17:143. doi: 10.1186/s13058-015-0650-8.

    The Angelina Jolie effect: how high celebrity profile can have a major impact on provision of cancer related services.

    Blog post: The Angelina Jolie effect (BioMed Central)

    • Risk assessment: Physicians discuss motivations for rising rates of prophylactic mastectomies.
    • Printz C.
    • Cancer. 2015 Jun 1;121(11):1721-2. doi: 10.1002/cncr.28996.
    • Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carriers.
    • Chai X, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C, Garber JE, Neuhausen SL, Matloff E, Eeles R, Tung N, Weitzel JN, Couch FJ, Hulick PJ, Ganz PA, Daly MB, Olopade OI, Tomlinson G, Blum JL, Domchek SM, Chen J, Rebbeck TR.
    • Breast Cancer Res Treat. 2014 Nov;148(2):397-406. doi: 10.1007/s10549-014-3134-0. Epub 2014 Oct 14.
    • The Angelina Jolie effect: how high celebrity profile can have a major impact on provision of cancer related services.
    • Evans DG, Barwell J, Eccles DM, Collins A, Izatt L, Jacobs C, Donaldson A, Brady AF, Cuthbert A, Harrison R, Thomas S, Howell A; The FH02 Study Group; RGC teams, Miedzybrodzka Z, Murray A; The FH02 Study Group; RGC Teams.
    • Breast Cancer Res. 2014 Sep 19;16(5):442. doi: 10.1186/s13058-014-0442-6.

    Comment, Letter:

    Longer term effects of the Angelina Jolie effect: increased risk-reducing mastectomy rates in BRCA carriers and other high-risk women.

    • Use of and mortality after bilateral mastectomy compared with other surgical treatments for breast cancer in California, 1998-2011.
    • Kurian AW, Lichtensztajn DY, Keegan TH, Nelson DO, Clarke CA, Gomez SL.
    • JAMA. 2014 Sep 3;312(9):902-14. doi: 10.1001/jama.2014.10707.

    Editorial, Comment:

    Contralateral prophylactic mastectomy: is it a reasonable option?

    • Timing of prophylactic hysterectomy-oophorectomy, mastectomy, and microsurgical breast reconstruction in BRCA1 and BRCA2 carriers.
    • Khansa I, Wang D, Coriddi M, Tiwari P.
    • Microsurgery. 2014 May;34(4):271-6. doi: 10.1002/micr.22195. Epub 2013 Oct 7.
    • Changes in specialists' perspectives on cancer genetic testing, prophylactic surgery and insurance discrimination: then and now.
    • Matloff ET, Bonadies DC, Moyer A, Brierley KL.
    • J Genet Couns. 2014 Apr;23(2):164-71. doi: 10.1007/s10897-013-9625-z. Epub 2013 Jul 13.

    Press: What’s Ahead for BRCA Genetic Testing and Counseling? (OncLive)

    • Risk reducing mastectomy, breast reconstruction and patient satisfaction in Norwegian BRCA1/2 mutation carriers.
    • Hagen AI, Mæhle L, Vedå N, Vetti HH, Stormorken A, Ludvigsen T, Guntvedt B, Isern AE, Schlichting E, Kleppe G, Bofin A, Gullestad HP, Møller P.
    • Breast. 2014 Feb;23(1):38-43. doi: 10.1016/j.breast.2013.10.002. Epub 2013 Nov 5.
    • Risk management options elected by women after testing positive for a BRCA mutation.
    • Garcia C, Wendt J, Lyon L, Jones J, Littell RD, Armstrong MA, Raine-Bennett T, Powell CB.
    • Gynecol Oncol. 2014 Feb;132(2):428-33. doi: 10.1016/j.ygyno.2013.12.014. Epub 2013 Dec 16.
    • Risk-reducing mastectomy in BRCA1/2 mutation carriers: Factors influencing uptake and timing.
    • van Driel CM, Eltahir Y, de Vries J, Jaspers JP, Oosterwijk JC, Mourits MJ, de Bock GH.
    • Maturitas. 2014 Feb;77(2):180-4. doi: 10.1016/j.maturitas.2013.10.017. Epub 2013 Nov 1.
    • International Rates of Breast Reconstruction After Prophylactic Mastectomy in BRCA1 and BRCA2 Mutation Carriers.
    • Semple J, Metcalfe KA, Lynch HT, Kim-Sing C, Senter L, Pal T, Ainsworth P, Lubinski J, Tung N, Eng C, Gilchrist D, Blum J, Neuhausen SL, Singer CF, Ghadirian P, Sun P, Narod SA; Hereditary Breast Cancer Clinical Study Group.
    • Ann Surg Oncol. 2013 Nov;20(12):3817-22. doi: 10.1245/s10434-013-3040-4. Epub 2013 Jun 6.
    • Variants of uncertain significance in BRCA testing: evaluation of surgical decisions, risk perception, and cancer distress.
    • Culver J, Brinkerhoff C, Clague J, Yang K, Singh K, Sand S, Weitzel J.
    • Clin Genet. 2013 Nov;84(5):464-472. doi: 10.1111/cge.12097. Epub 2013 Feb 20.
    • Trends in the use of bilateral mastectomy in England from 2002 to 2011: retrospective analysis of hospital episode statistics.
    • Neuburger J, Macneill F, Jeevan R, van der Meulen JH, Cromwell DA.
    • BMJ Open. 2013 Aug 1;3(8). pii: e003179. doi: 10.1136/bmjopen-2013-003179.
    • Impact of family history on choosing risk-reducing surgery among BRCA mutation carriers.
    • Singh K, Lester J, Karlan B, Bresee C, Geva T, Gordon O.
    • Am J Obstet Gynecol. 2013 Apr;208(4):329.e1-6. doi: 10.1016/j.ajog.2013.01.026. Epub 2013 Jan 17.
    • Breast and ovarian cancer risk management in a French cohort of 158 women carrying a BRCA1 or BRCA2 germline mutation: patient choices and outcome.
    • This P, de la Rochefordière A, Savignoni A, Falcou MC, Tardivon A, Thibault F, Alran S, Fourchotte V, Fitoussi A, Couturaud B, Dolbeault S, Salmon RJ, Sigal-Zafrani B, Asselain B, Stoppa-Lyonnet D.
    • Fam Cancer. 2012 Sep;11(3):473-82. doi: 10.1007/s10689-012-9539-1.
    • Comparison of patient characteristics and outcomes of contralateral prophylactic mastectomy and unilateral total mastectomy in breast cancer patients.
    • Chung A, Huynh K, Lawrence C, Sim MS, Giuliano A.
    • Ann Surg Oncol. 2012 Aug;19(8):2600-6. doi: 10.1245/s10434-012-2299-1. Epub 2012 Mar 7.
    • How should we discuss genetic testing with women newly diagnosed with breast cancer? Design and implementation of a randomized controlled trial of two models of delivering education about treatment-focused genetic testing to younger women newly diagnosed with breast cancer.
    • Watts KJ, Meiser B, Mitchell G, Kirk J, Saunders C, Peate M, Duffy J, Kelly PJ, Gleeson M, Barlow-Stewart K, Rahman B, Friedlander M, Tucker K; TFGT Collaborative Group.
    • BMC Cancer. 2012 Jul 28;12:320. doi: 10.1186/1471-2407-12-320.
    • Predictive factors for BRCA1/BRCA2 mutations in women with ductal carcinoma in situ.
    • Bayraktar S, Elsayegh N, Gutierrez Barrera AM, Lin H, Kuerer H, Tasbas T, Muse KI, Ready K, Litton J, Meric-Bernstam F, Hortobagyi GN, Albarracin CT, Arun B.
    • Cancer. 2012 Mar 15;118(6):1515-22. doi: 10.1002/cncr.26428. Epub 2011 Aug 25.

    Comments from NSGC Discussion Forum Cancer SIG

    Subject: Does anyone have a good reference for the occurence of DCIS in hereditary cancer syndromes?

    • Long-term outcomes of BRCA1/BRCA2 testing: risk reduction and surveillance.
    • Schwartz MD, Isaacs C, Graves KD, Poggi E, Peshkin BN, Gell C, Finch C, Kelly S, Taylor KL, Perley L.
    • Cancer. 2012 Jan 15;118(2):510-7. doi: 10.1002/cncr.26294. Epub 2011 Jun 29.